Melbourne, Australia; 17 October, 2011: Patrys Limited (ASX: PAB; “the Company”), a clinical stage biopharmaceutical company focused on the development of novel treatments for cancer, is pleased to announce the publication and presentation of data from the scale-up and manufacture of its lead IgM antibody candidate PAT-SM6.
The data will be published in the December 2011 issue of BioProcess International, a leading biopharmaceutical journal.
This is the second scientific paper Patrys has published on outcomes from its IgM antibody manufacturing platform, and further documents how Patrys has successfully overcome the challenges of producing IgMs, which are more complex and six times larger than the more commonly produced IgGs. Confirmation of the scalability of Patrys’ process is a significant technical advancement that broadens the versatility of the Company’s antibody manufacturing platform.
In March 2010, Patrys appointed Laureate Biopharmaceutical Services, Inc. to scale-up and manufacture PAT-SM6 for preclinical and clinical purposes. In May 2011, the first batch of PAT-SM6 was manufactured and released for use. This material is being used in the current PAT-SM6 melanoma trial underway at the Royal Adelaide Hospital and the Princess Alexandra Hospital, Brisbane.
“We are excited at the opportunity to share the data from the scale-up and manufacturing of our lead IgM antibody, PAT-SM6. The successful completion of our first 250 litre run was essential to advancing PAT-SM6. The work in the paper outlines the production, scalability and purification processes for this antibody,” said Michael Conner, Patrys VP of Manufacturing.
In addition to the publication, the data will be presented at the BioProcess International Conference and Exhibition, on November 1, 2011 by Michael Conner of Patrys and Dr. Michiel E. Ultee, Chief Scientific Officer at Laureate Biopharmaceutical Services, Inc.